Entrada Therapeutics, Inc.
Securities Investigation
Investors who purchased or acquired TRDA securities are encouraged to come forward.
Investigation opened May 12, 2026
Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Entrada Therapeutics, Inc. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Entrada Therapeutics, Inc. (TRDA) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Entrada Therapeutics, Inc. (“Entrada” or “the Company”) (NASDAQ: TRDA). Investors who purchased Entrada securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Entrada has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
- 1Whether Entrada Therapeutics, Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- 2Whether Entrada Therapeutics, Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
- 3Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
Key Dates
An investigation is not a lawsuit. If a complaint is filed, a lead plaintiff deadline will be set and posted here.
Why Did TRDA Stock Drop?
On May 7, 2026, Entrada issued a press release announcing “topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of the Phase 1/2 ELEVATE-44-201 clinical study.” Although Entrada characterized the results as “positive”, the study only showed a 2.36% increase in production of dystrophin, a protein that is critical for muscle protection and does not appear at adequate levels in Duchenne patients—significantly less than necessary to make the drug competitive against other treatments. Following this news, Entrada’s stock price fell $9.18 per share, or 57.27%, to close at $6.85 per share on May 7, 2026.
How Is Entrada Therapeutics, Inc. (NASDAQ: TRDA) Stock Trading Today?
What Happens After You Contact Us?
Tell us about your purchase
Takes about a minute. Share count and statements are optional.
We review your transactions
Our team reviews your trades at no cost or obligation.
We keep you updated
If a case is filed, we'll contact you about your options and any deadlines.
Submitting information does not create an attorney-client relationship. Our firm works on a contingency fee basis, and you do not need to have sold your shares to contact us.
How Does BG&G Help Investors in Securities Fraud Investigations?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace."
Frequently Asked Questions
Has a lawsuit been filed against Entrada Therapeutics, Inc.?
No complaint has been filed. BG&G is investigating whether investors may have claims. If a securities class action is filed, this page will be updated with the court, class period, and lead plaintiff deadline.
What does a securities investigation mean?
The firm is reviewing public disclosures, stock price movements, and other information to determine whether a company or its officers may have violated the federal securities laws. An investigation does not mean wrongdoing has been established.
Why should I contact the firm now?
Sharing your information early lets us review your transactions and notify you promptly if a case is filed, including any deadline to seek appointment as lead plaintiff.
Does it cost anything?
No. Our firm works on a contingency fee basis, and there is no cost or obligation to contact us.
I sold my TRDA shares. Can I still contact you?
Yes. Potential claims generally depend on when you purchased and whether you suffered a loss, not on whether you still hold the shares.
What documents should I have ready?
Brokerage statements or trade confirmations showing your TRDA purchases, sales, and holdings, including dates, share counts, and prices.